MiR-132 is significantly downregulated in the middle and late stages of AD, leading to the upregulation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKB) and increased ERK1/2 and BACE1 activity in AD patients (Salta et al., 2016; Zhu Q. B. et al., 2016). Here, BACE1 is linked to Alzheimer disease.